Research suggests: Corona vaccine for children - provides only moderate efficacy

A 11-5-year-old vaccine against corona reduces the chance of illness by 51% - lower efficacy compared to adult vaccines.

However, efficacy is likely sufficient in the face of serious illness.

It was also found that the protection from the omicron strain is lower compared to the protection from the delta strain

Meirav Cohen

30/06/2022

Thursday, June 30, 2022, 12:00 p.m.

• Share on Facebook

• Share on WhatsApp

• Share on Twitter

• Share on Email

• Share on general

• Comments

  Comments

In the video: a briefing by Prof. Zarqa following the increase in morbidity in Corona (Photo: GPO)

A corona vaccine reduces the chance of illness among children aged 11-5 by 51%, according to a study by Clalit Health Fund published today (Thursday).

It was also found that the incidence of symptomatic infection between seven days and 21 days decreased by 48%.

The members of the IDF are expected to convene tomorrow to discuss the approval of toddler vaccinations between the ages of six months and five years

. In all age groups in the study, the data show that better protection was recorded in the younger age group, ages five to six, compared with the older age group, ages ten to 11.

More about the corona virus

• Record infestation in Corona Since early April, the number of serious patients has almost doubled within a week

• Prof. Ash: We can start talking about a new wave of Corona

• Revolution in the world of facial treatments: artificial intelligence and RF technology in a home device from B-Cure Laser

51% protection.

A child gets vaccinated against Corona (Photo: Reuven Castro)

In the study, the data of 94,728 vaccinated children aged 11-5 were compared with the same amount of children at these ages, who were carefully adjusted and did not receive any vaccine against corona.

This is one of the first and large-scale studies evaluating the effectiveness of the Pfizer vaccine (BNT162b2), in a reduced dose adapted for children aged 5-11, while the omicron strain (B.1.1.529) was common in Israel.

The study was conducted by the Clalit Research Institute in collaboration with researchers from Harvard University, researchers from the University of Padua in Italy and the University of London.

Prof. Ran Blitzer, head of Clalit's Innovation Division and director of the research institute, added that the study determined that the vaccine for children provided less protection against infection with the Omicron strain, in contrast to the Delta strain.

"Previous studies we conducted at Clalit have shown high efficacy for the first doses of the vaccine in protecting against symptomatic Delta strain infection in adolescents, this is several weeks after the second dose of the vaccine," he said.

"It is difficult to determine which part of the decrease in infection protection can be attributed to the reduced dose, especially at higher ages in this age group, aged 10-11, and what part can be attributed to differences in vaccine efficacy versus Omicron versus Delta strain."

More on Walla!

After FDA approval: Experts will discuss toddler vaccines against corona

To the full article

• news

• Corona

Tags

• Corona virus

• Vaccine for corona

• General

• Ren Blitzer